Q2 2025 Earnings Call Transcript July 31, 2025 Biogen Inc. misses on earnings expectations. Reported EPS is $ EPS, ...

Investing.com – Oppenheimer hat die Einstufung "Outperform" und das Kursziel von 205,00 US-Dollar für die Aktie von Biogen (NASDAQ: BIIB) nach der Veröffentlichung der Finanzergebnisse für das zweite ...

Discover key insights from Biogen's Q2 2025 earnings call: strong product launches, pipeline advancements, raised EPS guidance, and resilient MS ...

Biogen (($CC:HTER)) announced an update on their ongoing clinical study. Biogen Inc. (BIIB) has announced an update on its ...

Biogen has announced that it has initiated a phase 3 study of investigational felzartamab in adults with primary membranous nephropathy (PMN), a severe antibody-mediated kidney disease. The 104-week ...

BIIB begins phase III dosing of felzartamab primary membranous nephropathy study, targeting a tough-to-treat condition with no approved therapies.

Global Phase 3 PROMINENT study will evaluate the efficacy and safety of felzartamab, as compared to tacrolimus, in adults with primary membranous nephropathy (PMN)There are currently no therapies ...

Dies ist die dritte Phase-3-Studie von Felzartamab, die Biogen in diesem Jahr gestartet hat, nach Studien zur Nierentransplantatabstoßung und IgA-Nephropathie.

This marks Biogen’s third Phase 3 trial of felzartamab launched this year, following studies in kidney transplant rejection and IgA nephropathy. The information in this article is based on a company ...

Global Phase 3 PROMINENT study will evaluate the efficacy and safety of felzartamab, as compared to tacrolimus, in adults with primary membranous nephropathy (PMN)There are currently no therapies ...